Abstract:Cyclin-dependent kinases (CDKs) belong to a family of multifunctional enzymes that control cell cycle modifications, transcription, and cell proliferation. Their dysfunctions result in different diseases like cancer making them an important drug target in oncology and beyond. The present study aims at identifying the selective inhibitors for ATP binding site in CDK proteins (CDK1, CDK2, CDK4, and CDK5) following a multi-target drug designing approach. Significant challenges lie in identifying the selective inhibitor for the ATP binding site as this region is highly conserved in all protein kinases. Molecular docking coupled with molecular dynamics simulation and free energy of binding calculations (MMPBSA/MMGBSA) were used to identify the potent competitive ATP binding site inhibitors. All the four proteins were docked against the library of drug-like compounds and the outcomes of the docking study were further analyzed by Molecular dynamics (total of 6μs) and MMPB/GBSA techniques. Five different inhibitors for structurally distant protein kinases, i.e. CDK1, CDK2, CDK4, and CDK5 are identified with the binding energy (ΔGbind-PB) in the range −18.24 to −28.43Kcal/mol. Mechanistic complexities associated with the binding of the inhibitor are unraveled by carefully analyzing the MD trajectories. It is observed that certain residues (Lys33, Asp127, Asp145, Tyr15, Gly16, Asn144) and regions are critical for the retention of inhibitors in active pocket, and significant conformational changes take place in the active site region as well as its neighbor following the entry of the ligand inside active pocket as inferred by RMSD and RMSF. It is observed that LIG3 and LIG4 are the best possible inhibitors as reflected from their high binding energy, interaction pattern, and their retention inside the active pocket. This study will facilitate the process of multi-target drug designing against CDK proteins and can be used in the development of potential therapeutics against different diseases.Graphical Communicated by Ramaswamy H. Sarma

Prediction of Allosteric Druggable Pockets of Cyclin-Dependent Kinases

Computational Study of Non-Catalytic T-loop Pocket on CDK Proteins for Drug Development

Novel Method to Identify Group-Specific Non-Catalytic Pockets of Human Kinome for Drug Design.

Targeting Cyclin-Dependent Kinases: From Pocket Specificity to Drug Selectivity

Gaining Insights into Key Structural Hotspots within the Allosteric Binding Pockets of Protein Kinases

Pharmacophore Identification, Docking and "in Silico" Screening for Novel Cdk1 Inhibitors

Identification of Potential ATP-competitive Cyclin-Dependent Kinase 1 Inhibitors: De Novo Drug Generation, Molecular Docking, and Molecular Dynamics Simulation.

Exploring multi-target inhibitors using in silico approach targeting cell cycle dysregulator–CDK proteins

HKPocket: Human Kinase Pocket Database for Drug Design

An allosteric cyclin E-CDK2 site mapped by paralog hopping with covalent probes

Improved Method for the Identification and Validation of Allosteric Sites.

Strategy toward Kinase-Selective Drug Discovery

Discovery of Potential Inhibitors of CDK1 by Integrating Pharmacophore-Based Virtual Screening, Molecular Docking, Molecular Dynamics Simulation Studies, and Evaluation of Their Inhibitory Activity

Identification of natural marine compounds as potential inhibitors of CDK2 using molecular docking and molecular dynamics simulation approach

Druggable exosites of the human kino-pocketome

Computational Analysis for Residue-Specific CDK2-Inhibitor Bindings

Cooperation of structural motifs controls drug selectivity in cyclin-dependent kinases: an advanced theoretical analysis

Pocket-Based Drug Design: Exploring Pocket Space

Break CDK2/Cyclin E1 Interface Allosterically with Small Peptides

High-throughput discovery and deep characterization of cyclin-CDK docking motifs

Crowdsourced mapping of unexplored target space of kinase inhibitors